Clinical Trials | January 01, 2026
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The accelerated review covers WCK 5222 for multiple critical infections
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The funding will accelerate Sinopia’s data-driven drug discovery efforts
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Subscribe To Our Newsletter & Stay Updated
